Genmab (GMAB) shares jumped 3.5% in after-hours trading Monday after the company and partner AbbVie said their chemotherapy-free lymphoma combination cut disease progression risk by 60% in a pivotal Phase 3 trial, a result that analysts said could meaningfully expand the drug’s addressable market.
The data from the EPCORE DLBCL-4 study positions epcoritamab as a potential new standard of care in second-line diffuse large B-cell lymphoma – the most common form of non-Hodgkin lymphoma – adding a durable new revenue stream to Genmab’s pipeline at a time when bispecific antibody competition is intensifying.
Key Takeaways
- Trial hit primary goal: 60% reduction in progression or death risk.
- GMAB shares rose ~3.5% in after-hours trading Monday.
- Epcoritamab already approved in 65+ territories for lymphoma indications.
Market Reaction & Context
GMAB closed Monday’s regular session at $26.02, before rising to $26.94 in after-hours trade – a gain of roughly 3.5% that outpaced the broader biotech sector on the day. 1 The iShares Biotechnology ETF (IBB) ended the session up approximately 0.6%, making Genmab’s after-hours move roughly six times the sector average.
The stock has faced headwinds in 2026 as investors have questioned the depth of epcoritamab’s commercial uptake relative to rival bispecifics. Monday’s data materially changes that calculus by expanding the drug’s potential label into a larger, earlier-line patient population. 2
Trial Design & Clinical Data
The EPCORE DLBCL-4 study is a global Phase 3, open-label, randomised trial that enrolled adults with relapsed or refractory diffuse large B-cell lymphoma who had received at least one prior line of therapy including anti-CD20 monoclonal antibody-containing chemotherapy. 1 It began on August 13, 2024, and remains ongoing.
The combination of epcoritamab – a subcutaneously administered T-cell engaging bispecific antibody – with lenalidomide was tested against investigator-selected standard-of-care regimens. The study met its primary endpoint with a hazard ratio of 0.40 (95% CI: 0.30-0.55), translating to the 60% reduction in the risk of disease progression or death. 1
Diffuse large B-cell lymphoma accounts for approximately 25-30% of all non-Hodgkin lymphoma cases globally, with roughly 25,000 new diagnoses annually in the United States alone. 1 Capturing even a fraction of second-line patients who are currently ineligible or unwilling to undergo chemotherapy represents a substantial commercial opportunity.
Pipeline Durability & Revenue Mix Implications
Epcoritamab, marketed as EPKINLY in the U.S. and Japan and as TEPKINLY in the European Union, already holds regulatory approval across more than 65 territories for certain lymphoma indications. 1 A positive label expansion into second-line DLBCL would supplement existing approvals and deepen the drug’s revenue contribution over a multi-year horizon – a key concern for long-horizon investors evaluating Genmab’s pipeline durability.
Under the co-development agreement, Genmab and AbbVie share commercial responsibilities in the U.S. and Japan, while AbbVie handles broader global commercialisation. This structure means epcoritamab royalties and profit-sharing represent a recurring, scalable component of Genmab’s revenue mix rather than a one-time milestone payment. 1
Regulatory Pathway & Next Steps
Genmab and AbbVie said they plan to engage with global regulatory authorities on the basis of the topline results. The companies said detailed data will be presented at a future medical congress, the timing of which has not been disclosed. 1
“The EPCORE DLBCL-4 trial met its primary objective, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival with the chemotherapy-free combination,” the companies said in their announcement. 1
Regulatory submissions in the U.S. and EU would likely follow the data presentation, with a potential approval decision setting up a phased commercial launch. Genmab has not provided formal revenue guidance tied to the expanded indication.
Conclusion
Monday’s trial readout gives Genmab a credible path to growing epcoritamab into a multi-indication franchise with durable cash flows – addressing one of the central questions overhanging the stock. For investors with a long time horizon, the key watch-points now shift to the speed of regulatory submissions, the breadth of the label Genmab secures, and whether the chemotherapy-free profile translates into real-world prescription momentum in a competitive bispecific market. 2
Not investment advice. For informational purposes only.
References
1Luke Juricic (Jun 29, 2026). “Genmab stock rises on positive lymphoma trial results”. Investing.com. Retrieved June 30, 2026.
2WSJ Business News (Jun 30, 2026). “Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial”. X (formerly Twitter) / The Wall Street Journal. Retrieved June 30, 2026.